Vikas Jaitak, PhD is an expert in Biochemistry at Central University of Punjab (India). As of October 2026, ScienceLeadR ranks Vikas Jaitak in the top 1% of experts in India for Breast Neoplasms and Breast Diseases. Vikas Jaitak has authored 92 publications, the most recent in 2026. SLR score: 345 (community average: 125). How the SLR is computed.

LeadR Profile

Vikas Jaitak, PhD Central University of Punjab India
345 ScienceLeadR Reputation 345
Network Map

Biochemistry

Subspecialties: Pharmacy - Oncology - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026

Source: PubMed

Central University of Punjab

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 92

Citations

Citations: 3 337 1st author: 6 Last author: 70 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Indazole Derivatives as Emerging Scaffolds for Anti-Breast Cancer Therapy: Synthesis, Structure-Activity Relationship, and Therapeutic Potential.
PMID 42956263 — breast neoplasms, structure-activity relationship, neoplasms, multiple chronic conditions, pharmacy, breast, therapeutics, indazoles
Arch Pharm (Weinheim)20260
Isoform-selective FGFR inhibition as pioneer in cancer therapy: heterocyclic scaffold optimization strategies, mechanistic insights, and future directions.
PMID 42944732 — pharmaceutical preparations, protein isoforms, chemistry, pharmaceutical, neoplasms, therapeutics, drug resistance
Future Med Chem20260
Pyrimidine-containing Heterocyclic Anticancer Agents: Systematic Development, SAR, and Mechanistic Pathways.
PMID 42706982 — cells, antineoplastic agents, chemistry, pharmaceutical, neoplasms, multiple chronic conditions, therapeutics
Mini Rev Med Chem20260
Structure-based elucidation of thiazine inhibitors targeting estrogen receptors alpha: pharmacophore modeling, virtual screening, molecular docking, MD, and DFT approach.
PMID 42566885 — estrogens, estrogen receptor alpha, pharmaceutical preparations, receptors, estrogen, neoplasms, tamoxifen
J Mol Graph Model20260
Emerging Molecular Targets and Recent Advancements for the Management of Depression.
PMID 42435254 — depression, antidepressive agents, therapeutics
Mol Neurobiol20260

LeadR Networks

Main global connection map